LGC

The deal marks the latest in a series of acquisition LGC has made in recent years to expand its presence on the nucleic acid chemistry market.

London-based LGC said that the acquisition increases its exposure to the next-generation sequencing and gene editing markets.

LGC will offer NuGen's single-primer enrichment technology for next-generation sequencing target enrichment.

LGC will supply DNA fragmentation instruments for clinical and agricultural biotechnology customers.

The company will integrate the oligonucleotide manufacturer with two of its existing sections to form a new Nucleic Acid Chemistry business unit.

The partners will evaluate several quality control assays for genome editing research, eventually creating a protocol for analyzing mutations in genomic DNA.

LGC said it plans to use Douglas Scientific's PCR and qPCR platforms to provide customers with enhanced high-throughput genotyping and qPCR instruments.

The two companies will use KeyGene's technology for the genetic analysis of field and vegetable crops.